Working… Menu

The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency (QUANTUM-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00532805
Recruitment Status : Completed
First Posted : September 20, 2007
Last Update Posted : January 23, 2018
National Center for Research Resources (NCRR)
Alpha-1 Foundation
Information provided by (Responsible Party):
Charlie Strange, Medical University of South Carolina

Brief Summary:
Individuals with a deficiency of alpha-1 antitrypsin (AAT) often develop emphysema. Traditional lung function tests may not be the most accurate way to measure the progression of emphysema. This study will compare high resolution computed tomography (CT) scans to spirometry to measure the progression of emphysema.

Condition or disease
Alpha-1 Antitrypsin Deficiency

Detailed Description:

AAT deficiency is a genetic disorder associated with emphysema. Spirometry, the lung function test that measures how well the lungs exhale air, is used to diagnose and track the progression of emphysema. Some studies have suggested that forced expiratory volume in 1 second (FEV1) measurements, a type of spirometry test, may lack accuracy in detecting disease progression in cases of severe AAT deficiency. Another method, high resolution chest CT scans, may be more accurate at measuring the progression of emphysema. The purpose of this study is to determine if high resolution CT scans are better at detecting the progression of emphysema than lung function tests. Results from this study may lead to the development of a more accurate way to assess lung tissue loss and may improve the understanding of lung destruction in AAT deficiency.

This study will last 4 years and will enroll people with AAT deficiency who have nearly normal lung function test results. Study visits, each lasting about 4 hours, will occur at baseline and months 6, 12, 18, 24, and 36. At each visit, participants will undergo lung function tests, a CT scan, blood collection, and a physical exam. Female participants will have urine collected for a pregnancy test. All participants will also complete questionnaires to assess health status and lung function. Study researchers will call participants every 2 months to collect information on lung disease symptoms and medication changes.

Layout table for study information
Study Type : Observational
Actual Enrollment : 49 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: QUANTitative Chest Computed Tomography UnMasking Emphysema Progression in Alpha-1 Antitrypsin Deficiency
Study Start Date : August 2007
Actual Primary Completion Date : February 2012
Actual Study Completion Date : April 2012

Primary Outcome Measures :
  1. CT density slope [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA

50 cc of serum at visits baseline, 6 months, 12 months, 18 months, 24 months and 36 months will be retained. These are kept at the University of Florida in the laboratory of Dr. Mark Brantly.

There is an associated but independent DNA collection that is done if the patient is willing through an independent study and consent process with the University of Florida Alpha-1 DNA and Tissue Bank. This is a public resource with a scientific advisory committee with samples available for researcher access.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with alpha-1 antitrypsin who have nearly normal lung function tests. Participants will be identified from patients of the investigators, physician referral, and the Alpha-1 Foundation Research Registry.

Inclusion Criteria:

  • Diagnosis of AAT deficiency, as determined by both of the following conditions:

    1. Serum A1-P1 levels less than 11uM or 80 mg/dL
    2. Protease inhibitor phenotype Z (PiZZ) or Znull phenotype confirmed by gene probe analysis. Previous serum levels and phenotype results are acceptable if documented from a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
  • FEV1 greater than or equal to 80% of the predicted value

Exclusion Criteria:

  • Pregnant or intending to become pregnant within 4 years of study entry
  • Previous lung transplantation
  • Sibling of a participant who is already enrolled in the study
  • Unable to attend scheduled clinic visits
  • Currently smokes cigarettes or marijuana or quit smoking cigarettes or marijuana in the 1 year prior to study entry
  • Current or planned use of oral tobacco products or nicotine replacement products
  • Evidence of significant long-term or acute inflammation outside the lung, including connective diseases, panniculitis, or acute infection
  • Unwilling to alter bronchodilator medications for 24 hours prior to scheduled quantitative CT (QCT) scans
  • Musculoskeletal disease that limits exercise by walking
  • Required to take any of the following medications within 48 hours of scheduled lung function testing: dicyclomine (Bentyl), propantheline (Pro-Banthine), mepenzolate (Cantil), methscopolamine (Pamine), and scopolamine (Transderm-Scop)
  • Known allergy or intolerance to tiotropium or albuterol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00532805

Layout table for location information
United States, Colorado
National Jewish Medical and Research Center
Denver, Colorado, United States
United States, Florida
University of Florida Medical Center
Gainesville, Florida, United States
United States, Massachusetts
Harvard/Brigham and Women's Hospital
Boston, Massachusetts, United States
United States, Ohio
Cincinnati Children's Medical Center
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
United States, Oregon
Oregon Health and Sciences University
Portland, Oregon, United States
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States
Sponsors and Collaborators
Medical University of South Carolina
National Center for Research Resources (NCRR)
Alpha-1 Foundation
Layout table for investigator information
Study Chair: Charlie Strange, MD Medical University of South Carolina
Layout table for additonal information
Responsible Party: Charlie Strange, Professor of Pulmonary Medicine, Medical University of South Carolina Identifier: NCT00532805    
Other Study ID Numbers: RDCRN 5701
1U54RR019498-01 ( U.S. NIH Grant/Contract )
First Posted: September 20, 2007    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018
Keywords provided by Charlie Strange, Medical University of South Carolina:
Alpha 1-Antitrypsin Deficiency
Additional relevant MeSH terms:
Layout table for MeSH terms
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Pathologic Processes